© 2026 Sinochem Nanjing Corporation,
All Right Reserved
|
HS Code |
777675 |
As an accredited 7-(4-Bromobenzoyl)-1,3-Dihydroindol-2-One factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | |
| Shipping | |
| Storage |
Competitive 7-(4-Bromobenzoyl)-1,3-Dihydroindol-2-One prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615371019725 or mail to admin@sinochem-nanjing.com.
We will respond to you as soon as possible.
Tel: +8615371019725
Email: admin@sinochem-nanjing.com
Flexible payment, competitive price, premium service - Inquire now!
Sometimes, a single molecule can unlock new directions for scientific work. 7-(4-Bromobenzoyl)-1,3-Dihydroindol-2-One falls in that territory. No gaudy claims needed — this compound has proven itself as a go-to intermediate across advanced organic synthesis, particularly where research teams push medicinal chemistry past the limits of older chemical scaffolds. High purity batches, often at 98% or better, ensure results you can trust in academic and industrial settings alike. By focusing on functional utility over generic claims, this compound carves a spot for itself among synthetic chemists who value reliability as much as novelty.
Details matter in chemical work. 7-(4-Bromobenzoyl)-1,3-Dihydroindol-2-One brings together several practical benefits. The presence of both an indolinone ring and a 4-bromobenzoyl moiety grants it usability in cross-coupling, heterocycle formation, and as a building block for kinase inhibitor analogues. Synthetic routes that feature this compound tend to avoid convoluted protection-deprotection steps, letting chemists keep projects moving rather than bogging down in protocol. Compared to similar indole derivatives, it provides a stable, reliable base for modifications through Suzuki, Heck, or Sonogashira reactions.
Physical characteristics land in a range that supports easy lab handling. Most batches come as a well-defined powder, neither too fluffy nor overly dense, with melting points in a moderate window, supporting both storage and weighing. That consistency cuts down on uncertainty. Once you’ve experienced the unpredictability of poorly characterized intermediates, a reliable input like this one saves hours or days — and plenty of frustration — each quarter.
Synthetic chemistry isn’t about magic solutions. It’s about finding the intersection of availability, reactivity, and practical workup. This compound gets special attention because it covers that ground where many laboratory intermediates fail. Researchers push for selective functionalization every day, and here, the aryl bromide opens up a menu of cross-coupling options. You don’t have to gamble on activation — the bromide group responds predictably under common catalytic conditions. In direct contrast to unbrominated analogues, this increases the diversity of derivatives you can prepare and screen.
In my own bench days, taking shortcuts with low-quality intermediates often led to gummed-up columns and awkward isolation steps. Good starting points shape not just the route but the mood of the lab — it only takes one run with a smooth workup and clean separation to appreciate why experienced chemists invest in properly characterized substrates. Young scientists might be tempted to cut corners for speed, but every time yield or selectivity collapses, the value of a tested compound stands out even more.
Options for indole-based starting materials have exploded in the last ten years. Still, only a smaller subset consistently delivers reliable reactivity in typical cross-coupling or addition chemistry. Some labs rely on simple indolinones or related carbocyclics, hoping to make up the difference through post-synthetic tweaks. That tends to burn more solvent, time, and energy. The inclusion of the 4-bromobenzoyl group here opens up paths that plain indolinones leave closed. Site-specificity follows naturally.
Similar products may offer either a plain aryl group or a non-halogenated benzoyl, but once you try to insert new connections or elaborate ring systems, the clean departure of the bromine (especially under palladium catalysis) tips the balance. Even considering price differences for brominated starting materials, most teams find the downstream benefits — avoiding low-yielding side reactions, wasting fewer purification rounds — make up the difference.
Solubility tends to stay within workable bounds for most common organic solvents, which means you won’t run into the annoying fate of cross-linking side reactions that plague some indole derivatives under heating. That’s not a minor point if you’ve ever had to run reactions at scale, then found out the intermediate clogs up a filter cake or resists extraction.
There’s a sense among researchers that pace keeps accelerating. Grant cycles shorten. Reviewers ask for more analogues, more thorough SAR, and often, faster generation of data. A bottleneck in preparing advanced intermediates throws a wrench into that flow, holding back creativity on the part of medicinal chemists or process teams. Reliable starting points do more than speed up individual reactions. They create room to think about optimization, rendering the “grunt work” fast and repeatable so scientific imagination can focus on newer, more impactful questions.
As chemical libraries grow, compounds like 7-(4-Bromobenzoyl)-1,3-Dihydroindol-2-One feed the pipeline for everything from anti-cancer screening programs to materials innovation. Each project taking shape around this molecule starts from a place of known behavior — an advantage when chasing regulatory approval or simply trying to explain reproducibility across international teams.
Some might shrug and wonder: why not grab the cheapest, most basic batch of indolinone and hack it closer to the target structure? That temptation pops up in academic and industrial circles. In practice, small corners cut in starting material quality or structure translate to headaches down the line. Poorly controlled impurity profiles, batch-to-batch inconsistencies, unclear melting points — these all turn simple synthesis into trial by fire.
By contrast, sourcing something like 7-(4-Bromobenzoyl)-1,3-Dihydroindol-2-One from a reputable, science-first supplier introduces certainty. You’re dealing with a molecule that’s been handled, analyzed, and delivered with research in mind. Instead of chasing cryptic yield drops or explaining every minor impurity to a team of skeptical colleagues, your time actually goes toward developing the next step. There’s an old saying among researchers: the best reaction is the one you don’t have to repeat. Clean, reliable starting points make that possible.
I remember working on a kinase inhibitor project that called for a library of analogues based on the oxindole scaffold. Indole derivatives demonstrated promise, but unhalogenated versions took days to tweak for every new substitution pattern. Switching to a brominated benzoyl approach, like what’s seen here, chopped preparation time in half for each subsequent analogue. The aryl bromide not only provided a clear anchor point for cross-coupling, but it also calmed down the workup phase — fewer inseparable byproducts, more consistent TLC, and a lot less time staring at cloudy filtrates hoping for crystals. At that point, the cost of upgrading the intermediate paid off just in reclaimed hours and better mood around the bench.
Colleagues would sometimes risk new, off-brand batches in the hope of shaving off expenses. Nine times out of ten, running these head-to-head experiments with a proper, well-defined intermediate like 7-(4-Bromobenzoyl)-1,3-Dihydroindol-2-One reaffirmed the classic wisdom: buy quality once, rather than chase solutions piecemeal. By using a single, well-characterized intermediate across multiple routes, the team improved both reproducibility and patentability for later-stage work.
Much of medicinal chemistry now revolves around iterative, stepwise modification of molecular frameworks. Libraries for biological screening — whether in cancer, antibiotic discovery, or neurological diseases — rely on diversity more than brute force. Starting with an intermediate that enables a variety of transformations creates natural leverage. Here, the 4-bromobenzoyl motif allows for quick expansion into families of analogues by amination, arylation, or cyclization, without constant reinvention of the synthetic wheel.
In material science, this compound opens up paths for preparing advanced polymers and electronic devices, especially where carefully tuned, electron-rich frameworks matter. Thin films and specialized coatings often demand starting materials that behave consistently batch after batch, and 7-(4-Bromobenzoyl)-1,3-Dihydroindol-2-One delivers on that front. Consistency supports physical characterization and downstream validation — crucial if new applications in organic electronics or diagnostic sensors are on the horizon.
Experienced chemists always look for a few key distinctions when choosing starting materials. Reactivity profile, isolation ease, and compatibility with downstream chemistry top the list. Compared to more generic indolinones, this compound passes the test by responding predictably under diverse reaction conditions. The brominated aryl enables standard palladium-catalyzed coupling strategies, letting synthetic teams build substantial compound libraries from a single intermediate.
Unlike some analogues that introduce steric hindrance or orthogonal protections, 7-(4-Bromobenzoyl)-1,3-Dihydroindol-2-One avoids common pitfalls. Its chemical stability removes headaches during purification, and it doesn’t decompose under gentle heat or exposure to standard solvents. These traits might seem mundane unless you’ve lost product to decomposition at a late stage, or had to start over from square one after a minor handling error. By integrating a substrate that behaves, research teams spend less time firefighting and more time on innovation.
Supply chain headaches factor into more project planning than most outside the industry realize. This intermediate now occupies inventory spaces at many synthesis-focused labs, not because it’s glamorous, but because it saves time and preserves budgets over the full timeline of a research campaign. Leadership teams appreciate predictable costs and timelines — and good intermediates help guarantee both.
Strong reproducibility comes from a mix of good lab habits and starting materials you don’t have to second-guess. Chemists across the world report that brominated substrates, particularly in the indolinone family, outperform their non-brominated cousins in coupling reactions, improving yields and selectivity. Journal articles and patents consistently reference 7-(4-Bromobenzoyl)-1,3-Dihydroindol-2-One for key steps in preparing kinase inhibitors, anti-inflammatory compounds, and advanced functional materials. By supporting both academic publication and scalable industrial projects, it lends versatility no “off-the-shelf” analogue quite matches.
It’s easy to overlook the everyday drudgery of weighing, dissolving, and filtering — until a batch clogs a filter or ruins an HPLC run. Reliable handling characteristics matter just as much as headline-grabbing reactivity, and teams who stick with 7-(4-Bromobenzoyl)-1,3-Dihydroindol-2-One report fewer blockages, better flow rates, and less downtime during scale-up. In-house studies reveal that, in Suzuki couplings, this compound delivers cleaner conversions than its closest indolinone alternatives, especially where steric bulk and solubility come into play. Data-driven choices make a difference, week after week and quarter after quarter.
Every synthetic route throws up obstacles: poor solubility, unpredictable reactivity, sensitivity to air or moisture, or scale-dependent behavior. By leaning on intermediates with stable, well-characterized properties, chemists avoid creating new headaches down the line. Sourcing your 7-(4-Bromobenzoyl)-1,3-Dihydroindol-2-One from trusted suppliers — those committed to detailed batch testing and transparent documentation — eliminates the noise of batch-to-batch variability.
In the event of route-specific hiccups, whether related to cross-coupling efficiency or product purification, the best approach relies on incremental optimization. Adjusting catalyst loadings, solvent choices, and purification protocols works best when the starting intermediate isn’t changing from one month to the next. A good intermediate, by refusing to introduce uncontrolled variables, actually raises the ceiling for creative problem-solving elsewhere. That’s one lesson repeated by group leaders and process chemists alike: controlling what you can pays long-term dividends.
As regulatory pressure tightens on both pharmaceutical R&D and industrial manufacturing, traceability becomes essential. 7-(4-Bromobenzoyl)-1,3-Dihydroindol-2-One typically arrives with analysis certificates detailing purity, moisture, and impurity profiles. This transparency reduces paperwork, smooths handoff between teams, and satisfies quality control without consuming time meant for real discovery.
Veterans in organic synthesis learn hard lessons about neglected details. Every project’s early stages look different — sometimes chasing blue-sky ideas, sometimes confirming literature routes, always moving under deadline. With every failed run, lab teams reconsider what inputs represent real value for both timeline and wallet. My experience lines up with countless conversations at scientific conferences: those who cut corners with intermediates almost always land in trouble, while teams building from trusted compounds outperform across multiple projects.
Tastes and fashions change in research, but sensible choices in early synthetic planning endure. 7-(4-Bromobenzoyl)-1,3-Dihydroindol-2-One earned its spot on many project shelves because it keeps work focused on discovery. Whether the task is churning through analogues for patent filings or charting new mechanistic ground for publication, reliable intermediates form an invisible backbone for meaningful breakthrough.
Looking beyond today’s reaction flask, the role of trusted intermediates keeps growing. Cross-disciplinary teams bring together organic synthesis, analytical chemistry, and biology; all depend on starting materials that won’t surprise or derail progress. As automated synthesis platforms expand and computational design makes inroads, the margin for error narrows. It’s no exaggeration to say that compounds like 7-(4-Bromobenzoyl)-1,3-Dihydroindol-2-One act as bridges between old-fashioned bench work and new, data-rich workflows.
I see research managers and senior chemists increasingly searching for intermediates proven in literature and lab, supported by clear data and visible provenance. Fewer surprises in starting materials grant more time and confidence in chasing real scientific difference. This is as true in startup biotech as in long-established academic labs. The more repetitive work relies on outcomes you can bet on, the freer teams become to take creative risks elsewhere.
7-(4-Bromobenzoyl)-1,3-Dihydroindol-2-One might not grab mainstream headlines, but for thousands of research teams worldwide, it fills a daily need: keep synthesis moving, reduce dead time, and sharpen the edge of exploration. Gimmicks and fancy claims fade fast; reliable performance, transparent data, and real-world experience keep this compound relevant. At a time when drug discovery, materials science, and chemical innovation cross more boundaries than ever, small choices in starting materials drive big differences in where new solutions come from next.
